Fertility Test Market Report and Forecast 2025-2034

Published Jul 27, 2025

Length 350 Pages

SKU # EMAR20319652

Description

The global fertility test market size was valued at USD 583.90 Million in 2024, driven by the increasing prevalence of infertility across the globe. The market is expected to grow at a CAGR of 7.60% during the forecast period of 2025-2034, with the values likely to rise from USD 628 Million in 2025 to USD 1214.68 Million by 2034.

Fertility Test: Introduction

Fertility testing is used to identify the issues that might be preventing a couple from conceiving. Fertility tests are available for males as well as females. It constitutes blood tests, pelvic examination, seme analysis, post-coital tests, laparoscopy, and hysteroscopy among others. It is often considered as an initial step to treat infertility and helps in comprehending the couple’s medical history better, enabling customised treatment for their specific condition.

Global Fertility Test Market Analysis

The rising infertility rates, owing to the fast-paced and sedentary lifestyle, and increased drug indulgence, have contributed to the market growth in recent years. The rising emphasis on career often leads to delayed pregnancies and ends up contributing to the growing infertility rates. The rising incidence of diseases like PCOS, PCOD, endometriosis, varicocele, and azoospermia is a key factor aiding the fertility test market growth.

With increasing advancements in the medical ecosystem, fertility tests have evolved over the period. Everything from hormonal tests to imaging tests is available to the masses nowadays. Owing to the rising popularity of self-diagnostic tests and telemedicine, at-home fertility tests are the latest addition to the market. Rising initiatives by various leading companies and the government is also supporting the fertility test market demand.

To combat the rising burden of male infertility, researchers have been looking into new methods of diagnosis for effective treatments. In June 2023, scientists discovered two specific proteins, unique to viable sperm. These ASPX and AKAP4 proteins help in the analysis of whether surgery for non-obstructive azoospermia would be successful or not. This diagnostic test also aligns with the non-invasive approach and enables better decision-making in healthcare professionals.

Global Fertility Test Market Segmentation

Fertility Test Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Products

Ovulation Predictor Kits
Fertility Monitors

Urine

Saliva

Blood

Market Breakup by Application

Male
Female

Market Breakup by End User

Home Care
Fertility Clinics
Hospitals

Market Breakup by Region

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Global Fertility Test Market Overview

Infertility affects 1 in every 6 people on the planet. It is noteworthy that the high-income countries have a higher infertility prevalence (around 17.8%), than low- and middle-income countries where it is approximately 16.5%. Consequently, the North American region, particularly United States and Canada have led the fertility test market share in the historical period. The changing lifestyles, delayed pregnancies, and increased substance consumption have also contributed to the rising market size.

Europe also holds a significant part of the fertility tests market owing to the region’s advanced healthcare system and rising awareness around fertility associated concerns spread by government as well as influential healthcare companies. The innovation and adoption of new technologies to combat the rising incidence of diseases such as PCOS, azoospermia, and endometriosis, among others is contributing to market growth.

Countries like China, Japan, India, and South Korea have been experiencing high growth in the market. Improving healthcare facilities, rising fertility awareness, evolving societal norms, and increasing disposable incomes are impacting the market value.

Global Fertility Test Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Swiss Precision Diagnostics
Church & Dwight Co., Inc.
Prestige Brands Holdings
bioZhena
Fairhaven Health
Fertility Focus
Geratherm Medical AG
Hilin Life Products
UEBE Medical
Churchill Pharmaceuticals, LLC.
Procter & Gamble Co.
Mankind Pharma Ltd.
Babystart Ltd.
Innevation Pty Ltd.
AdvaCare Pharma

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
*Please Note:* The report will take 5 business days to complete, after order confirmation.

1 Preface: 1.1 Objectives of the Study; 1.2 Key Assumptions; 1.3 Report Coverage – Key Segmentation and Scope; 1.4 Research Methodology
2 Executive Summary
3 Global Fertility Test Market Overview: 3.1 Global Fertility Test Market Historical Value (2018-2024); 3.2 Global Fertility Test Market Forecast Value (2025-2034)
4 Global Fertility Test Market Landscape: 4.1 Fertility Test: Developers Landscape; 4.1.1 Analysis by Year of Establishment; 4.1.2 Analysis by Company Size; 4.1.3 Analysis by Region; 4.2 Fertility Test: Product Landscape; 4.2.1 Analysis by Type; 4.2.2 Analysis by Applications
5 Global Fertility Test Market Dynamics: 5.1 Market Drivers and Constraints; 5.2 SWOT Analysis; 5.3 Porter’s Five Forces Model; 5.4 Key Demand Indicators; 5.5 Key Price Indicators; 5.6 Industry Events, Initiatives, and Trends; 5.7 Value Chain Analysis
6 Global Fertility Test Market Segmentation: 6.1 Global Fertility Test Market by Products; 6.1.1 Market Overview; 6.1.2 Ovulation Predictor Kits; 6.1.3 Fertility Monitors; 6.1.3.1 Urine; 6.1.3.2 Saliva; 6.1.3.3 Blood; 6.2 Global Fertility Test Market by Application; 6.2.1 Market Overview; 6.2.2 Male; 6.2.3 Female; 6.3 Global Fertility Test Market by End User; 6.3.1 Market Overview; 6.3.2 Home Care; 6.3.3 Fertility Clinics; 6.3.4 Hospitals; 6.4 Global Fertility Test Market by Region; 6.4.1 Market Overview; 6.4.2 North America; 6.4.3 Europe; 6.4.4 Asia Pacific; 6.4.5 Latin America; 6.4.6 Middle East and Africa
7 North America Fertility Test Market: 7.1 Market Share by Country; 7.2 United States of America; 7.3 Canada
8 Europe Fertility Test Market: 8.1 Market Share by Country; 8.2 United Kingdom; 8.3 Germany; 8.4 France; 8.5 Italy; 8.6 Others
9 Asia Pacific Fertility Test Market: 9.1 Market Share by Country; 9.2 China; 9.3 Japan; 9.4 India; 9.5 ASEAN; 9.6 Australia; 9.7 Others
10 Latin America Fertility Test Market: 10.1 Market Share by Country; 10.2 Brazil; 10.3 Argentina; 10.4 Mexico; 10.5 Others
11 Middle East and Africa Fertility Test Market: 11.1 Market Share by Country; 11.2 Saudi Arabia; 11.3 United Arab Emirates; 11.4 Nigeria; 11.5 South Africa; 11.6 Others
12 Regulatory Framework: 12.1 Regulatory Overview; 12.1.1 US FDA; 12.1.2 EU EMA; 12.1.3 INDIA CDSCO; 12.1.4 JAPAN PMDA; 12.1.5 Others
13 Patent Analysis: 13.1 Analysis by Type of Patent; 13.2 Analysis by Publication year; 13.3 Analysis by Issuing Authority; 13.4 Analysis by Patent Age; 13.5 Analysis by CPC Analysis; 13.6 Analysis by Patent Valuation; 13.7 Analysis by Key Players
14 Grants Analysis: 14.1 Analysis by year; 14.2 Analysis by Amount Awarded; 14.3 Analysis by Issuing Authority; 14.4 Analysis by Grant Application; 14.5 Analysis by Funding Institute; 14.6 Analysis by NIH Departments; 14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis: 15.1 Analysis by Trial Registration Year; 15.2 Analysis by Trial Status; 15.3 Analysis by Trial Phase; 15.4 Analysis by Therapeutic Area; 15.5 Analysis by Geography
16 Funding and Investment Analysis: 16.1 Analysis by Funding Instances; 16.2 Analysis by Type of Funding; 16.3 Analysis by Funding Amount; 16.4 Analysis by Leading Players; 16.5 Analysis by Leading Investors; 16.6 Analysis by Geography
17 Partnership and Collaborations Analysis: 17.1 Analysis by Partnership Instances; 17.2 Analysis by Type of Partnership; 17.3 Analysis by Leading Players; 17.4 Analysis by Geography
18 Supplier Landscape: 18.1 Swiss Precision Diagnostics; 18.1.1 Financial Analysis; 18.1.2 Product Portfolio; 18.1.3 Demographic Reach and Achievements; 18.1.4 Mergers and Acquisitions; 18.1.5 Certifications; 18.2 Church & Dwight Co., Inc.; 18.2.1 Financial Analysis; 18.2.2 Product Portfolio; 18.2.3 Demographic Reach and Achievements; 18.2.4 Mergers and Acquisitions; 18.2.5 Certifications; 18.3 Prestige Brands Holdings; 18.3.1 Financial Analysis; 18.3.2 Product Portfolio; 18.3.3 Demographic Reach and Achievements; 18.3.4 Mergers and Acquisitions; 18.3.5 Certifications; 18.4 bioZhena; 18.4.1 Financial Analysis; 18.4.2 Product Portfolio; 18.4.3 Demographic Reach and Achievements; 18.4.4 Mergers and Acquisitions; 18.4.5 Certifications; 18.5 Fairhaven Health; 18.5.1 Financial Analysis; 18.5.2 Product Portfolio; 18.5.3 Demographic Reach and Achievements; 18.5.4 Mergers and Acquisitions; 18.5.5 Certifications; 18.6 Fertility Focus; 18.6.1 Financial Analysis; 18.6.2 Product Portfolio; 18.6.3 Demographic Reach and Achievements; 18.6.4 Mergers and Acquisitions; 18.6.5 Certifications; 18.7 Geratherm Medical AG; 18.7.1 Financial Analysis; 18.7.2 Product Portfolio; 18.7.3 Demographic Reach and Achievements; 18.7.4 Mergers and Acquisitions; 18.7.5 Certifications; 18.8 Hilin Life Products; 18.8.1 Financial Analysis; 18.8.2 Product Portfolio; 18.8.3 Demographic Reach and Achievements; 18.8.4 Mergers and Acquisitions; 18.8.5 Certifications; 18.9 UEBE Medical; 18.9.1 Financial Analysis; 18.9.2 Product Portfolio; 18.9.3 Demographic Reach and Achievements; 18.9.4 Mergers and Acquisitions; 18.9.5 Certifications; 18.10 Churchill Pharmaceuticals, LLC.; 18.10.1 Financial Analysis; 18.10.2 Product Portfolio; 18.10.3 Demographic Reach and Achievements; 18.10.4 Mergers and Acquisitions; 18.10.5 Certifications; 18.11 Procter & Gamble Co.; 18.11.1 Financial Analysis; 18.11.2 Product Portfolio; 18.11.3 Demographic Reach and Achievements; 18.11.4 Mergers and Acquisitions; 18.11.5 Certifications; 18.12 Mankind Pharma Ltd.; 18.12.1 Financial Analysis; 18.12.2 Product Portfolio; 18.12.3 Demographic Reach and Achievements; 18.12.4 Mergers and Acquisitions; 18.12.5 Certifications; 18.13 Babystart Ltd.; 18.13.1 Financial Analysis; 18.13.2 Product Portfolio; 18.13.3 Demographic Reach and Achievements; 18.13.4 Mergers and Acquisitions; 18.13.5 Certifications; 18.14 Innevation Pty Ltd.; 18.14.1 Financial Analysis; 18.14.2 Product Portfolio; 18.14.3 Demographic Reach and Achievements; 18.14.4 Mergers and Acquisitions; 18.14.5 Certifications; 18.15 AdvaCare Pharma; 18.15.1 Financial Analysis; 18.15.2 Product Portfolio; 18.15.3 Demographic Reach and Achievements; 18.15.4 Mergers and Acquisitions; 18.15.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight): 20.1 Very Small Companies; 20.2 Small Companies; 20.3 Mid-Sized Companies; 20.4 Large Companies; 20.5 Very Large Companies
21 Payment Methods (Additional Insight): 21.1 Government Funded; 21.2 Private Insurance; 21.3 Out-of-Pocket

Pricing

Currency Rates

Single User Email from Publisher $4,949
Global Site License Email from Publisher $6,969

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now